Research Progress of 223-Ra in the Treatment of Bone Metastases from Desmoplasia-resistant Prostate Cancer

VernacularTitle:镭-223治疗去势抵抗性前列腺癌骨转移的研究进展
Author: Chang LU ¹ ; Ran ZHANG ; Li ZHANG ; Jiaxin DING ; Yue SUN ; Zhuoling RAN ; Yuxuan ZHENG ; Lin YU ; Xu GAO ; Jing XIE ; Huan ZHOU ; Jian GONG
Author Information

1. 沈阳药科大学药物流行病与临床药物评价课题组,沈阳 110016
Publication Type:Journal Article
Keywords: Radium-223; Radionuclide; Desmoplasia-resistant prostate cancer
From: Herald of Medicine 2025;44(3):446-451
CountryChina
Language:Chinese
Abstract: Prostate cancer is one of the most common male urological malignancies,in which bone metastasis of desmo-plasia-resistant prostate cancer is an important stage in the progression of the disease,which seriously affects the quality of life and survival of patients.With the development of nuclide therapy technology in recent years,223-Ra,as a new type of alpha-targeted therapy,has shown good efficacy in the treatment of desmoplasia-resistant prostate cancer bone metastasis.The purpose of this pa-per is to review the characteristics,mechanism of action,treatment,and the main research results of its treatment of desmoplasia-resistant prostate cancer bone metastasis,and provide a comprehensive review of the clinical application of 223-Ra in the treatment of desmoplasia-resistant prostate cancer bone metastasis for the clinical application of 223-Ra in prostate cancer bone metastasis.